8-K: Tharimmune and Intract Pharma Announce Merger to Create Oral Biologics Leader

Tharimmune and Intract Pharma have signed a non-binding letter of intent to merge, aiming to create a leading oral biologics company.

Summary

• Tharimmune, Inc. and Intract Pharma Ltd. have announced a non-binding, exclusive letter of intent to merge.
• Tharimmune will acquire all outstanding shares of Intract in exchange for newly issued restricted common stock.
• Intract shareholders will own 49% of the combined entity, which will retain the name Tharimmune, Inc.
• The merger is expected to close in the first quarter of 2025.
• The combined company will focus on developing oral biologics, leveraging Intract's delivery platform and Tharimmune's clinical-stage assets.
• The merger aims to expand Tharimmune's product pipeline and strengthen its position in the multibillion-dollar biologics market.
• Tharimmune believes the merger will lead to significant value creation over the next 24 months.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook on the merger, highlighting potential synergies and value creation. The language is optimistic and forward-looking, suggesting a strong belief in the success of the combined entity.

Positives

• The merger combines Tharimmune's clinical-stage assets with Intract's oral biologics delivery platform.
• The combined company is expected to have a strong clinical pipeline and a unified management team.
• The merger is anticipated to create significant shareholder value.
• Oral biologics have the potential to improve patient compliance and quality of life.
• Intract's delivery platform protects biologics as they pass through the gastrointestinal tract.

Negatives

• The letter of intent is non-binding, meaning the merger is not guaranteed.
• The merger is subject to the execution of a definitive agreement and closing conditions.
• The combined company will need to integrate two different organizations.

Risks

• The merger may not close in the anticipated timeframe or at all.
• The combined company may face challenges in integrating the two businesses.
• The development of oral biologics is subject to regulatory and clinical risks.
• The combined company may not achieve the expected synergies or value creation.
• The company is subject to risks outlined in their annual report on Form 10-K.

Future Outlook

The combined company expects to reach multiple milestones with significant value-creation potential over the next 24 months. The merger is expected to close in the first quarter of 2025.

Management Comments

• Randy Milby, CEO of Tharimmune, stated the merger will deliver best-in-class therapeutic solutions and set new industry standards.
• Vipul Yadav, CEO of Intract Pharma, expressed excitement about partnering with Tharimmune to advance their pipeline.

Industry Context

The merger reflects a trend in the biotechnology industry towards combining innovative delivery platforms with promising therapeutic candidates. This move aims to capitalize on the growing market for oral biologics, which offer advantages over traditional injectable treatments.

Comparison to Industry Standards

• The merger is similar to other biotech mergers that aim to combine complementary technologies and pipelines.
• The focus on oral biologics aligns with a growing trend in the industry to develop more patient-friendly drug delivery methods.
• Companies like Oramed Pharmaceuticals and Rani Therapeutics are also developing oral delivery platforms for biologics, indicating a competitive landscape.
• The success of the merger will depend on the combined company's ability to execute on its clinical development plans and commercialize its products effectively.

Stakeholder Impact

• Shareholders of both companies are expected to benefit from the potential value creation.
• Patients may benefit from the development of more convenient oral biologics.
• Employees of both companies will be integrated into the new organization.
• The merger may impact the competitive landscape for other companies in the biologics market.

Next Steps

• The companies will work towards executing a definitive agreement.
• The merger is expected to close in the first quarter of 2025.
• The combined company will focus on advancing its clinical pipeline and developing oral biologics.

Key Dates

Keywords

merger, oral biologics, biotechnology, pharmaceutical, Tharimmune, Intract Pharma, acquisition, clinical-stage, delivery platform, shareholder value